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ABSTRACT: 
When children require hospital admission, many receive medications with nephrotoxic 
potential. As such, this can translate into an increased risk of acute kidney injury. In this 
context, acute kidney injury is hospital acquired, often iatrogenic, and portends risk of 
adverse outcomes. The Nephrotoxic Injury Negated by Just-in-Time Action study 
implemented a multicenter hospital-wide quality improvement initiative to detect and 
reduce nephrotoxin exposure in children aimed at decreasing the rates of potentially 
avoidable acute kidney injury. This commentary explores the findings and implications 
of the Nephrotoxic Injury Negated by Just-in-Time Action study 
KEY WORDS: quality, safety, nephrotoxin, acute kidney injury, implementation  
EDITORIAL: 
“It is foolish to be convinced without evidence, but it is equally foolish to refuse to be 
convinced by real evidence.”  
Upton Sinclair, author of “The Jungle”  
The delivery of acute medical care in hospital settings is complex and often associated 
with substantial risk of medical errors and adverse events.1 
The rate of adverse events among adult hospitalized patients has been estimated at 7.5 
events per 100 hospitalizations, of which close to 2 in 5 were adjudicated as being 
avoidable.2 In hospitalized children, the rate of adverse events approaches 10%, is 
more common among academic centers and less often deemed to be preventable.3  
Acute kidney injury (AKI) is no exception to these observations. AKI can often be 
considered an iatrogenic hospital-acquired condition and has been shown to be 
associated with short-term complications including higher mortality, longer hospital stay, 
incremental costs and downstream risk of chronic kidney disease (CKD).4 Indeed, 
hospital-acquired AKI is currently being considered as a quality indicator of harm by the 
Centers for Medicare and Medicaid Services.5  
Drugs with nephrotoxic potential are commonly prescribed for hospitalized children and 
are often a necessity; however, their administration is associated with risk of iatrogenic 
AKI.6 Nephrotoxin-induced AKI in turn is associated with greater risk of death, 
prolonged hospitalization and costs. This risk can be mitigated, in part, by enhanced 
monitoring of children perceived to be at greater risk leveraged through wide-scale 
implementation of electronic health records.7 Many children, by virtue of their disease 
and treatments, may inherently be at greater risk of AKI; however, these children can 
also be readily identified.8 As such, there should be little tolerance for potentially 
avoidable episodes of AKI that occur in hospitalized children.  
In this issue, Goldstein and colleagues present the multi-center Nephrotoxic Injury 
Negated by Just-in time Action (NINJA) program9, extending their prior work that 
reduced avoidable AKI episodes by 62% in a single US center.8 NINJA engaged nine 
diverse children’s hospitals across the United States to implement hospital-wide (non-
ICU) screening (i.e., “trigger tool”) for nephrotoxin exposure. This was defined as receipt 
of an aminoglycoside for three or more days or three or more nephrotoxin medications 
(from a defined list) on the same calendar day. The program involved an inter-
professional two-day learning session, integrated bundled intervention aimed to mitigate 
nephrotoxin exposure including a medication review (medication substitution if feasible) 
and obtaining a daily serum creatinine during exposure. The program aimed to reduce 
AKI, defined as an increase in serum creatinine of 50% within seven days or 0.3 mg/dL 
(26.5 µmol/L) within 48 hours following initial exposure. The primary endpoint was the 
number of exposed children with AKI per 1000 non-critically ill patient-hospital days. 
This was complemented by several additional process and outcomes measures. A 
statistical change in the primary outcome was conservatively estimated by observing 
eight consecutive bi-weekly rates in the same direction either above or below the 
baseline rate, and further confirmed using autoregressive integrated moving average 
(ARIMA) modeling. 
The NINJA program was effectively and sustainably implemented across nine 
institutions; however, as expected, there was variation in time to maturity and reporting. 
Overall, there was a 23.8% reduction in the rates of AKI (change from 1.7 to 1.3 AKI 
episodes per 1000 patient hospital days) and AKI rates per exposure (36.7% reduction), 
despite variable rates of nephrotoxin exposures over the >600,000 hospital-days 
observed. The program estimated 242 episodes of AKI were avoided with program 
implementation over the 2-year study, assuming the baseline rates of AKI would have 
persisted. These reductions in AKI rates are particularly notable bearing in mind the 
intervention required increased testing of serum creatinine, which could have resulted in 
ascertainment bias leading to an apparent increase in AKI rates.10 Indeed, this 
phenomenon is a well-recognized early step in quality improvement. This was observed 
in some of the centres, after which AKI rates fell as the intervention became more 
embedded demonstrating that initiatives focused on improving quality of care for 
children at risk of AKI can improve outcomes. The lack of serum creatinine testing at 
baseline in children at risk further highlights that suboptimal AKI care remains common 
in routine clinical practice. 
The authors are to be congratulated on their successful delivery of a multicentre quality 
improvement project, which itself is a considerable achievement. The NINJA program 
also nicely highlights some of challenges in performing such a study. Firstly, there was 
variation between centres. Individual sites varied in their observed reduction in AKI 
rates following implementation of the intervention, largely contingent on their baseline 
rates. Three sites with low baseline AKI rates relative to post-implementation rates 
showed no further reduction; whereas those with higher baseline rates showed 
improvement. In addition, the effectiveness of complex interventions may have some 
dependency on the local context in which they are introduced - there are examples of 
AKI bundles appearing to work in some settings but not others.10 Correspondingly, 
some flexibility was required in implementing the intervention across different centres 
(e.g., the method for the trigger tool). As expected with a hospital-wide approach, it was 
difficult to achieve 100% compliance in all aspects of the intervention across all centres. 
Despite this, benefits were still seen, and it remains uncertain as to whether even larger 
gains would have been seen with greater uptake and in settings with higher baseline 
AKI rates. These observations reinforce how quality improvement initiatives, such as 
NINJA, necessitate a careful appreciation of local culture with concomitant evaluation of 
the barriers and/or facilitators of successful implementation, and an approach to monitor 
and report these. Another consideration is the sheer spectrum of medications 
associated with altered kidney function, and our relative under-appreciation of their 
synergistic potential to contribute to AKI. This may represent a yet to be explored 
source of variation in the observed reduction in AKI rates.   
Some additional questions arise from these results. To date, quality improvement 
initiatives such as NINJA have focused on short-term outcomes. However, we could 
speculate that a reduction in rates of AKI, avoidance of more severe AKI and/or 
shortening of AKI duration may translate into future reduced mortality or lower incidence 
of downstream CKD. This remains to be investigated in future studies with longer follow-
up. In addition, whilst is it logical that the NINJA intervention should be applicable to all 
populations at risk of AKI, it has not yet been tested in adult populations to demonstrate 
its wider generalizability. Moreover, following a change in practice, it is important to 
consider potential unintended consequences arising as a result of the intervention (e.g. 
increased rates of sepsis associated with alternative choices in antibiotics).  
The findings of NINJA strongly suggest that a clinically meaningful proportion of 
nephrotoxin-related AKI events are avoidable, children at risk can be readily identified 
and that a relatively simple intervention can translate into substantial reductions in 
unnecessary harm. NINJA also reinforces how the EHR can be leveraged to trigger 
alerts that identify children at risk of AKI and to potentially intervene to mitigate 
preventable episodes of AKI. Applying this new knowledge may help hospitalised 
children navigate a “safer” jungle.  
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